Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Eylea | aflibercept | Regeneron Pharmaceuticals | N-125387 RX | 2011-11-18 | 2 products |
Eylea HD | aflibercept | Regeneron Pharmaceuticals | N-761355 RX | 2023-08-18 | 1 products |
Zaltrap | Ziv-Aflibercept | Sanofi | N-125418 RX | 2012-08-03 | 2 products |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
macular edema | — | D008269 | — |
diabetic retinopathy | EFO_0003770 | D003930 | — |
Expiration | Code | ||
---|---|---|---|
aflibercept, Eylea, Regeneron Pharmaceuticals, Inc. | |||
2030-02-08 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | 3 | 8 | 11 | 24 | 47 |
Macular edema | D008269 | — | — | — | 4 | 9 | 8 | 10 | 30 |
Edema | D004487 | — | R60.9 | — | 2 | 8 | 6 | 4 | 20 |
Wet macular degeneration | D057135 | EFO_0004683 | — | — | — | 3 | 6 | 10 | 19 |
Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | 4 | 1 | 7 | 12 |
Choroidal neovascularization | D020256 | — | — | — | 1 | 1 | 1 | 3 | 6 |
Pathologic neovascularization | D009389 | — | — | — | — | 1 | 1 | 3 | 5 |
Polypoidal choroidal vasculopathy | D000092342 | — | — | — | — | — | 4 | 1 | 5 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 3 | 1 | 4 |
Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Retinal diseases | D012164 | — | H35.9 | — | — | 3 | — | 3 | 6 |
Premature birth | D047928 | EFO_0003917 | O60 | — | — | 2 | — | 2 | 4 |
Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | — | 2 | — | 2 | 4 |
Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 2 | — | 1 | 3 |
Neovascular glaucoma | D015355 | EFO_1001060 | — | — | — | 2 | — | 1 | 3 |
Myopia | D009216 | EFO_0003927 | H52.1 | — | — | 1 | — | 1 | 2 |
Eye diseases | D005128 | EFO_0003966 | H44 | — | — | 1 | — | 1 | 2 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 2 | — | — | 2 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 2 | — | — | 2 |
Retinal degeneration | D012162 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Retinitis pigmentosa | D012174 | — | H35.52 | — | 1 | — | — | — | 1 |
Retinitis | D012173 | — | H30.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Retinal neovascularization | D015861 | — | H35.05 | — | — | — | — | 1 | 1 |
Caregiver burden | D000084802 | — | — | — | — | — | — | 1 | 1 |
Newborn infant diseases | D007232 | — | — | — | — | — | — | 1 | 1 |
Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | — | 1 | 1 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
Endophthalmitis | D009877 | — | — | — | — | — | — | 1 | 1 |
Vision disorders | D014786 | — | H53.11 | — | — | — | — | 1 | 1 |
Low vision | D015354 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Aflibercept |
INN | aflibercept |
Description | Aflibercept, sold under the brandname Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and Europe.
|
Classification | Protein |
Drug class | receptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1742982 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB08885 |
UNII ID | 15C2VL427D (ChemIDplus, GSRS) |